Pathogen-related signal transduction pathways of dendritic cells: Perspectives for cancer immunotherapy

Current Signal Transduction Therapy

Volumn 3, Issue 2, 2008, Pages 133-137

  Kato, Tomonori ^a   Ueda, Yasuji ^a   Kinoh, Hiroaki ^a   Tsukada, Kaori ^a   Ichikawa, Tomohiko ^a   Yonemitsu, Yoshikazu ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer immunotherapy; Dendritic cell; RIG I; RNA virus; SOCS; TLRs

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; JANUS KINASE; PATTERN RECOGNITION RECEPTOR; RETINOIC ACID INDUCIBLE PROTEIN I; RNA HELICASE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3; VIRUS RNA;

ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL MATURATION; DENDRITIC CELL; DENDRITIC CELL ACTIVATION; DENDRITIC CELL BASED IMMUNOSTIMULATORY RNA VIROTHERAPY; GENE ACTIVATION; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNOSTIMULATION; INNATE IMMUNITY; LUNG METASTASIS; MOLECULAR RECOGNITION; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; REVIEW; RNA VIRUS; SENDAI VIRUS; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 54949124968     PISSN: 15743624     EISSN: None     Source Type: Journal    
DOI: 10.2174/157436208784223116     Document Type: Review

References (47)

1. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124: 783-801.
2. Kawai T, Akira S. Innate immune recognition of viral infection. Nat Immunol 2006; 7: 131-137.
3. Honda K, Takaoka A, Taniguchi T. Type I interferon gene induction by the interferon regulatory factor family of transcription factors. Immunity 2006; 25: 349-360.
4. Kaisho T, Akira S. Toll-like receptor function and signaling. J Allergy Clin Immunol 2006; 117: 979-987.
5. Janeway CA, Medzhitov R. Innate immune recognition. Ann Rev Immunol 2002; 20: 197-216.
6. Akira S, Takala K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4: 499-511.
7. Wagner H. The immunobiology of the TLR9 subfamily. Trends Immunol 2004; 25: 381-386.
8. Schulz O, Diebold SS, Chen M, et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 2005; 433: 887-892.
9. Wang T, Town T, Alexopoulou L, Anderson JF, Fikrig E, Flavell RA. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat Med 2004; 10: 1366-1373.
10. Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004; 303: 1526-1529.
11. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis E, Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004; 303: 1529-1531.
12. Lund JM, Alexopoulou L, Sato A, et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci USA 2004; 101: 5598-5603.
13. Hornung V, Guenthner-Biller M, Bourquin C, et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR 7. Nat Med 2005; 11: 263-270.
14. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Ann Rev Immunol 2002; 20: 709-760.
15. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408: 740-745.
16. Krug A, French AR, Barchet W, et al. TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function. Immunity 2004; 21: 107-119.
17. Lund J, Sato A, Akira S, Medzhitov R, Iwasaki A. Toll-like receptor 9-mediated recognition of HSV-2 by plasmacytoid dendritic cells. J Exp Med 2003; 198: 513-520.
18. Yamamoto M, Sato S, Hemmi H, et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 2003; 301: 640-643.
19. Hoebe K, Du X, Georgel P, et al. Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature 2003; 424: 743-748.
20. Hemmi H, Takeuchi O, Sato S, et al. The roles of two IkappaB kinase-related kinases in lipopolysaccharide and double stranded RNA signaling and viral infection. J Exp Med 2004; 199: 1641-1650.
21. Kato H, Sato S, Yoneyama M, et al. Cell type-specific involvement of RIG-I in antiviral response. Immunity 2005; 23: 19-28.
22. Yoneyama M, Kikuchi M, Natsukawa T, et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004; 5: 730-737
23. Yoneyama M, Kikuchi M, Matsumoto K, et al. Shared and unique functions of the DExD/H-Box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J Immunol 2005; 175: 2851-2858.
24. Rothenfusser S, Goutagny N, DiPerna G, et al. The RNA helicase Lgp2 inhibits TLR-independent sensing of viral replication by retinoic acid-inducible gene-I. J Immunol 2005; 175: 5260-5268.
25. Kato H, Sato S, Yoneyama M, et al. Cell type specific involvement of RIG-I in antiviral response. Immunity 2005; 23: 19-28.
26. Kato H, Takeuchi O, Sato S, et al. Differential role of MDA5 and RIG-I in the recognition of RNA viruses. Nature 2006; 441: 101-105.
27. Gitlin L, Barchet W, Gilfillan S, et al. Essential role of mda-5 in type I IFN responses to polyriboinosinic: polyribocytidylic acid and encephalomyocarditis picornavirus. Proc Natl Acad Sci USA 2006; 103: 8459-8464.
28. Hornung V, Ellegast J, Kim S, et al. 5′-Triphosphate RNA is the ligand for RIG-I. Science 2006; 5801: 994-997.
29. Meylan E, Curran J, Hofmann K, et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 2005; 437: 1167-1172.
30. Kawai T, Takahashi K, Sato S, et al. IPS-1; an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol 2005; 6: 981-988.
31. Seth RB, Sun L, Ea CK, Chen ZJ. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF3. Cell 2005; 122: 669-682.
32. Xu LG, Wang YY, Han KJ, Li LY, Zhai Z, Shu HB. VISA is an adapter protein required for virus-triggered IFN-beta signaling. Mol Cell 2005; 19: 727-740.
33. Saha SK, Pietras EM, He JQ, et al. Regulation of antiviral responses by a direct and specific interaction between TRAF3 and Cardif. EMBO J 2006; 25: 3257-3263.
34. Balachandran S, Thomas E, Barber GN. A FADD-dependent innate immune mechanism in mammalian cells. Nature 2004; 432: 401-485.
35. Takahashi K, Kawai T, Kumar H, Sato S, Yonehara S, Akira S. Roles of Caspase-8 and Caspase-10 in antiviral innate immune responses. J Immunol 2006; 176: 4520-4524.
36. Shibata S, Okano S, Yonemitsu Y, et al. Induction of efficient antitumor immunity using dendritic cells activated by Sendai virus and its modulation of exogenous interferon-beta gene. J Immunol 2006; 177: 3564-3576.
37. Yoneyama Y, Ueda Y, Akutsu Y, et al. Development of immunostimulatory virotherapy using non-transmissible Sendai virus-activated dendritic cells. Biochem Biophys Res Commun 2007; 355: 129-135.
38. Kubo M, Hanada T, Yoshimura A. Suppressors of cytokine signaling and immunity. Nat Immunol 2003; 4: 1169-1176.
39. Alexander WS, Hilton DJ. The Role of Suppressors of Cytokine Signaling (SOCS) Proteins in Regulation of the Immune Response. Ann Rev Immunol 2004; 22: 503-529.
40. Greenhalgh CJ, Hilton DJ. Negative regulation of cytokine signaling. J Leukoc Biol 2001; 70: 348-356.
41. Ryo A, Suizu F, Yoshida Y, et al. Regulation of NF-κB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol Cell 2003; 12: 1413-1426.
42. Marine JC, Topham DJ, McKay C, et al. SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality. Cell 1999; 98: 609-616.
43. Alexander WS, Starr R, Fenner JE, et al. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 1999; 98: 597-608.
44. Naka T, Tsutsui H, Fujimoto M, et al. SOCS-1/SSI-1-deficient NKT cells participate in severe hepatitis through dysregulated cross-talk inhibition of IFN-gamma and IL-4 signaling in vivo. Immunity 2001; 14: 535-545.
45. Hanada T, Yoshida H, Kato S, et al. Suppressor of cytokine signaling-1 is essential for suppressing dendritic cell activation and systemic autoimmunity. Immunity 2003; 19: 437-450.
46. Shen L, Evel-Kabler K, Strube R, Chen SY. Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat Biotechnol 2004; 22: 1546-1553.
47. Kinjyo I, Hanada T, Inagaki-Ohara K, et al. SOCS1/JAB is a negative regulator of LPS-induced macrophage activation. Immunity 2002; 17: 583-591.